DP
NKTR icon

Diadema Partners’s Nektar Therapeutics NKTR Stock Holding History

Diadema Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,000
Closed -$4.27M – 176
2025
Q3 		$4.27M Buy
+75,000
New +$2.48M 1.09% 33
2025
Q1 		– Sell
-46,595
Closed -$609K – 141
2024
Q4 		$650K Buy
+46,595
New +$822K 0.28% 69

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diadema Partners's NKTR Position: Q4 2025 in Review

Diadema Partners sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 75,000 shares — an estimated $4.27M sold.

Diadema Partners first reported a position in NKTR in Q4 2024 and held it in 2 quarters. The position peaked at $4.27M in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Diadema Partners reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 75,000 Nektar Therapeutics shares in Q4 2025, an estimated $4.27M.
  • Diadema Partners first reported a position in Nektar Therapeutics in Q4 2024 and held it in 2 quarters.
  • Diadema Partners's Nektar Therapeutics position peaked at $4.27M in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.